World Investment Advisors Lowers Holdings in DexCom, Inc. (NASDAQ:DXCM)

World Investment Advisors lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 33,993 shares of the medical device company’s stock after selling 1,073 shares during the period. World Investment Advisors’ holdings in DexCom were worth $2,644,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Forvis Mazars Wealth Advisors LLC grew its position in shares of DexCom by 0.7% during the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock worth $1,359,000 after buying an additional 118 shares in the last quarter. Principal Securities Inc. grew its holdings in DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after acquiring an additional 135 shares in the last quarter. Larson Financial Group LLC increased its position in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the last quarter. Level Four Advisory Services LLC raised its holdings in shares of DexCom by 1.1% in the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company’s stock valued at $1,026,000 after purchasing an additional 150 shares in the last quarter. Finally, TD Private Client Wealth LLC lifted its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after purchasing an additional 167 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the sale, the executive vice president now owns 105,602 shares of the company’s stock, valued at approximately $7,432,268.76. This trade represents a 10.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last three months. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Performance

Shares of DXCM opened at $59.83 on Friday. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $141.99. The stock has a market capitalization of $23.38 billion, a P/E ratio of 41.84, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company’s fifty day moving average is $80.14 and its two-hundred day moving average is $76.87.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Cfra Research upgraded DexCom to a “hold” rating in a research note on Friday, March 21st. Canaccord Genuity Group increased their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.